688189 南新制药
2023/122022/122021/122020/122019/12

盈利能力分析
净资产收益率 ROE (%)0.285-5.823-10.83213.27232.274
总资产报酬率 ROA (%)0.203-3.859-7.6788.81112.078
投入资产回报率 ROIC (%)0.212-4.094-8.2379.73914.691

边际利润分析
销售毛利率 (%)84.72585.78887.12589.80988.613
营业利润率 (%)0.995-10.512-28.85212.81910.773
息税前利润/营业总收入 (%)1.692-9.810-28.73413.63112.362
净利润/营业总收入 (%)0.800-13.968-24.53913.0479.612

收益指标分析
经营活动净收益/利润总额(%)1,530.576-52.66046.545109.703106.185
价值变动净收益/利润总额(%)-196.0197.610-1.5516.1080.000
营业外收支净额/利润总额(%)2.5640.7390.1051.8401.251

偿债能力分析
流动比率 (X)3.0042.3082.3914.4891.316
速动比率 (X)2.9382.2662.3004.3501.219
资产负债率 (%)25.04833.67634.58222.38156.363
带息债务/全部投入资本 (%)20.13929.32128.97117.82349.149
股东权益/带息债务 (%)394.832239.254243.183458.485100.230
股东权益/负债合计 (%)302.869199.680189.065341.81472.069
利息保障倍数 (X)2.524-12.573-194.41923.8248.510

营运能力分析
应收账款周转天数 (天)307.531339.743297.907155.04161.323
存货周转天数 (天)87.724160.282215.745148.334115.681